Observational studyBMC geriatrics2024
Evaluation of Sarcopenia screening indices as predictors of mortality in older patients with Alzheimer's disease.
Observational study in BMC geriatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sarcopenia in cognitive disorders: Toward a shared pathophysiological framework.Osteoporosis and sarcopenia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThe study evaluated the effectiveness of the sarcopenia indices neutrophils/lymphocytes, platelets/lymphocytes, AST/ALT, and creatinine (Cr)/ cystatin C (CysC)*100 in predicting mortality in hospitalized patients with Alzheimer's disease (AD) aged 60 years or older. MEASUREMENTS: This retrospective observational survey was undertaken in a teaching hospital in western China from January 1, 2017, to December 30, 2022. The neutrophil/lymphocyte, platelet/lymphocyte, AST/ALT, and Cr/CysC*100 ratios were used to assess the presence of sarcopenia, with the upper quartiles used as the cutoff value. Information on all-cause mortality was obtained through telephone interviews or electronic medical records between June 1, 2024, and June 20, 2024. Overall survival (OS) represented the time from hospital admission to death/final follow-up. Cox proportional hazards models were applied to determine the relationships between the above parameters and mortality from all causes.
resultsThe information on 523 patients with AD was retrieved from the electronic medical record system. Of these, 329 were finally enrolled, all of whom were hospitalized and over the age of 60 years. The use of Cr/Cys C*100 as a sarcopenia indicator was found to be effective in predicting mortality (24.39% vs. 13.77% for patients with sarcopenia vs. those without, P = 0.024). However, the application of neutrophils/lymphocytes, platelets/lymphocytes, and AST/ALT as indicators showed no marked differences between the sarcopenia and non-sarcopenia participants. After further logistic regression analysis and correction of possible variables, participants with sarcopenia had an increased risk of death relative to those without (HR = 2.179, 95%CI: 1.175-4.044). CONCLUSIONS AND IMPLICATIONS: This study showed that only Cr/CysC*100 was effective in the prediction of mortality in older individuals with AD and sarcopenia and that neutrophils/lymphocytes, platelets/lymphocytes, and AST/ALT were not effective as predictors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.